Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data

[1] Franken M(2012)Similarities and differences between five European drug reimbursement systems Int. J. Technol. Assess. Health Care 28 349-357

[2] Le Polain M(2013)Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation Health Policy 109 263-269

[3] Cleemput I(2014)Early benefit assessment of pharmaceuticals in Germany: manufacturers’ expectations versus the Federal Joint Committee’s decisions Med. Decis. Making 34 1030-1047

[4] Koopmanschap M(2014)Early benefit assessment of new drugs in Germany—results from 2011 to 2012 Health Policy 116 147-153

[5] Henschke C(2012)Differences in external price referencing in Europe: a descriptive overview Health Policy 104 50-60

[6] Sundmacher L(2012)The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy Med. Care 50 1060-1070

[7] Busse R(2012)From evidence assessments to coverage decisions? The case example of glinides in Germany Health Policy 104 27-31

[8] Fischer KE(2012)Qualitative Studien in der Versorgungsforschung—Diskussionspapier, Teil 1: gegenstandsbestimmung [Qualitative research in health services research—discussion paper, part 1: what is the idea?] Gesundheitswesen 74 510-515

[9] Stargardt T(1990)EuroQol—a new facility for the measurement of health-related quality of life Health Policy 16 199-208

[10] Hörn H(1993)The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J. Natl. Cancer Inst. 85 365-376

[1] Franken M(2012)Similarities and differences between five European drug reimbursement systems Int. J. Technol. Assess. Health Care 28 349-357

[2] Le Polain M(2013)Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation Health Policy 109 263-269

[3] Cleemput I(2014)Early benefit assessment of pharmaceuticals in Germany: manufacturers’ expectations versus the Federal Joint Committee’s decisions Med. Decis. Making 34 1030-1047

[4] Koopmanschap M(2014)Early benefit assessment of new drugs in Germany—results from 2011 to 2012 Health Policy 116 147-153

[5] Henschke C(2012)Differences in external price referencing in Europe: a descriptive overview Health Policy 104 50-60

[6] Sundmacher L(2012)The use of patient-reported outcomes (PRO) within comparative effectiveness research: implications for clinical practice and health care policy Med. Care 50 1060-1070

[7] Busse R(2012)From evidence assessments to coverage decisions? The case example of glinides in Germany Health Policy 104 27-31

[8] Fischer KE(2012)Qualitative Studien in der Versorgungsforschung—Diskussionspapier, Teil 1: gegenstandsbestimmung [Qualitative research in health services research—discussion paper, part 1: what is the idea?] Gesundheitswesen 74 510-515

[9] Stargardt T(1990)EuroQol—a new facility for the measurement of health-related quality of life Health Policy 16 199-208

[10] Hörn H(1993)The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J. Natl. Cancer Inst. 85 365-376